[1] Ironomycin was shown to induce ferroptosis in breast cancer cell lines and its mechanism of action involves the targeting of lysosomal iron.

[2] Ironomycin kills breast cancer stem cells in mice, and is more potent in vitro and in vivo than its parent anti-bacterial natural product salinomycin.

Ironomycin and to a lesser extend salinomycin targeted cancer stem cells responsible for metastasis and relapse.

[3] The mechanism of action by which ironomycin and salinomycin kill cancer stem cells involves lysosomal iron sequestration, leading to the production of reactive oxygen species, lysosome membrane permeabilization and ferroptosis in breast cancer.

These candidate drugs abolished the capacity of HMLER CD24low to form colonies at low concentrations and ironomycin prevented these cells from developing tumorsphere in suspension, a well-established characteristic of cancer stem cells, at a low dose (ie.